RedHill Biopharma (RDHL) – Hot FDA News
-
RedHill Biopharma (RDHL) Opaganib Phase 2/3 Study in Severe COVID-19 Patients Did Not Meet Its Primary Endpoint
-
RedHill Biopharma (RDHL) Says Opaganib Demonstrates Complete Inhibition of SARS-CoV-2
-
-
-
-
-
-
-
-
-
-
-
Back to RDHL Stock Lookup